Amgen's Horizon buyout delayed again, pushing closure possibly to December

When Amgen revealed its intention to buy Horizon Therapeutics in 2022's largest biopharma buyout, executives with the California-based drugmaker said they hoped to close the deal in the first half of 2023. Now, thanks to a Federal Trade Commission (FTC) lawsuit and court scheduling, the companies are targeting mid-December.